Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT06626243
Official study title

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

Study summary

The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy. There are no risks for the patients, as this is a retrospective data collection.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 29, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Scientific Institute San Raffaele

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Scientific Institute San Raffaele
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
Treatment approach
Immunotherapy→Surgery→
Study topics
Before surgery (neoadjuvant)→After surgery (adjuvant)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024
  • Received neoadjuvant chemo-immunotherapy or immunotherapy alone
  • Age \>= 18 years old at the moment of surgery
Reasons someone may not be able to joinExclusion criteria

Age \<18 years old at the moment of surgery

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Baptist Health South FloridaMiami, Florida
  • Memorial Sloan Kettering Cancer CenterNew York, New York
  • West Virginia UniversityMorgantown, West Virginia
  • Istituto Clinico HumanitasRozzano, Milan
  • Scientific Institute Ospedale San RaffaeleMilan
  • Regina Elena National Cancer InstituteRome

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 29, 2024. Always confirm current availability with the study team.

View original record ↗